$CDTX
Cidara Therapeutics, Inc. Stock $cdtx

$cdtx Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000161061818000011 Filed on February 27, 2018

Income Statement

Concept	2018 Q1	2016 Q4	2016 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.610M	$3.040M	$3.610M
YoY Change	14.24%	28.81%	47.95%
% of Gross Profit
Research & Development	$13.20M	$11.31M	$8.729M
YoY Change	28.86%	49.6%	29.01%
% of Gross Profit
Depreciation & Amortization	$140.0K	$180.0K	$180.0K
YoY Change	-30.0%	5.88%	80.0%
% of Gross Profit
Operating Expenses	$16.81M	$14.35M	$12.34M
YoY Change	25.47%	44.57%	33.99%
Operating Profit	-$16.81M	-$14.35M	-$12.34M
YoY Change	25.47%	44.57%	33.99%
Interest Expense	$61.00K	-$40.00K	$109.0K
YoY Change		-166.67%	230.3%
% of Operating Profit
Other Income/Expense, Net	$61.00K	-$41.00K	$109.0K
YoY Change		-168.33%	230.3%
Pretax Income	-$16.75M	-$14.39M	-$12.23M
YoY Change	25.0%	45.8%	33.37%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.75M	-$14.39M	-$12.23M
YoY Change	25.01%	45.87%	33.28%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$801.8K	-$879.0K	-$879.2K
COMMON SHARES
Basic Shares Outstanding	20.77M shares	16.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$66.20M	$104.6M	$79.30M
YoY Change	-26.53%	-2.7%	-30.68%
Cash & Equivalents	$52.22M	$85.37M	$24.62M
Short-Term Investments	$14.00M	$19.30M	$54.70M
Other Short-Term Assets	$2.500M	$800.0K	$1.300M
YoY Change	108.33%	14.29%	44.44%
Inventory
Prepaid Expenses
Receivables	$288.0K	$0.00
Other Receivables	$0.00
Total Short-Term Assets	$68.99M	$105.4M	$80.58M
YoY Change	-24.42%	-2.61%	-30.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$936.0K	$1.374M	$1.463M
YoY Change	-27.55%	-18.41%	-5.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$321.0K	$190.0K	$190.0K
YoY Change	68.95%	163.89%	160.27%
Total Long-Term Assets	$1.257M	$1.564M	$1.653M
YoY Change	-15.18%	-10.93%	1.85%
TOTAL ASSETS
Total Short-Term Assets	$68.99M	$105.4M	$80.58M
Total Long-Term Assets	$1.257M	$1.564M	$1.653M
Total Assets	$70.25M	$107.0M	$82.23M
YoY Change	-24.27%	-2.74%	-29.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.999M	$2.909M	$2.957M
YoY Change	56.85%	-6.01%	121.0%
Accrued Expenses	$4.516M	$3.338M	$3.033M
YoY Change	31.28%	135.9%	66.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.100M
YoY Change
Total Short-Term Liabilities	$11.52M	$8.909M	$8.232M
YoY Change	67.28%	49.13%	92.56%
LONG-TERM LIABILITIES
Long-Term Debt	$7.800M	$9.800M	$0.00
YoY Change	-20.41%
Other Long-Term Liabilities		$80.00K	$85.00K
YoY Change		-9.09%	-3.41%
Total Long-Term Liabilities	$7.800M	$80.00K	$85.00K
YoY Change	10300.0%	-9.09%	-3.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.52M	$8.909M	$8.232M
Total Long-Term Liabilities	$7.800M	$80.00K	$85.00K
Total Liabilities	$19.33M	$18.78M	$8.317M
YoY Change	15.23%	209.85%	90.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$166.1M	-$93.66M	-$79.30M
YoY Change	55.18%	105.86%	122.57%
Common Stock	$217.1M	$181.8M	$153.2M
YoY Change	18.59%	21.7%	3.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.92M	$88.18M	$73.92M
YoY Change
Total Liabilities & Shareholders Equity	$70.25M	$107.0M	$82.23M
YoY Change	-24.27%	-2.74%	-29.71%

Cashflow Statement

Concept	2018 Q1	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	-$16.75M	-$14.39M	-$12.23M
YoY Change	25.01%	45.87%	33.28%
Depreciation, Depletion And Amortization	$140.0K	$180.0K	$180.0K
YoY Change	-30.0%	5.88%	80.0%
Cash From Operating Activities	-$14.72M	-$11.72M	-$7.690M
YoY Change	1.38%	73.89%	5.34%
INVESTING ACTIVITIES
Capital Expenditures	$31.00K	-$110.0K	-$70.00K
YoY Change	-73.28%	-76.09%	-87.27%
Acquisitions
YoY Change
Other Investing Activities	$480.0K	$35.50M	$3.160M
YoY Change	-95.79%	607.17%	-106.33%
Cash From Investing Activities	$450.0K	$35.38M	$3.100M
YoY Change	-96.01%	675.88%	-106.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$6.440M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.470M	37.08M	-60.00K
YoY Change	9142.86%	13633.33%	50.0%
NET CHANGE
Cash From Operating Activities	-14.72M	-11.72M	-7.690M
Cash From Investing Activities	450.0K	35.38M	3.100M
Cash From Financing Activities	6.470M	37.08M	-60.00K
Net Change In Cash	-$7.803M	60.74M	-4.650M
YoY Change	146.23%	-3280.1%	-91.96%
FREE CASH FLOW
Cash From Operating Activities	-$14.72M	-$11.72M	-$7.690M
Capital Expenditures	$31.00K	-$110.0K	-$70.00K
Free Cash Flow	-$14.75M	-$11.61M	-$7.620M
YoY Change	0.79%	84.87%	12.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14488987	shares
CY2016Q4	cdtx	Classof Warrantor Right Percentageof Principalof Debt Usedto Calculate Numberof Shares Issuedby Warrant ClassofWarrantorRightPercentageofPrincipalofDebtUsedtoCalculateNumberofSharesIssuedbyWarrant	0.02
CY2016Q4	cdtx	Classof Warrantor Right Periodof Average Closing Price Usedto Calculate Numberof Shares Issuedby Warrant ClassofWarrantorRightPeriodofAverageClosingPriceUsedtoCalculateNumberofSharesIssuedbyWarrant	P30D
CY2016Q4	cdtx	Classof Warrantor Right Term ClassofWarrantorRightTerm	P10Y
CY2017	cdtx	Common Stock Dividends In Arrears Or Default CommonStockDividendsInArrearsOrDefault	0	USD
CY2017	cdtx	Contractual Obligation Contract Termination Notice Period ContractualObligationContractTerminationNoticePeriod	P30D
CY2015	cdtx	Deferred Initial Public Offering Costs DeferredInitialPublicOfferingCosts	234000	USD
CY2016	cdtx	Deferred Initial Public Offering Costs DeferredInitialPublicOfferingCosts	0	USD
CY2017	cdtx	Deferred Initial Public Offering Costs DeferredInitialPublicOfferingCosts	0	USD
CY2015	cdtx	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	0	USD
CY2016	cdtx	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	0	USD
CY2017	cdtx	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	17334000	USD
CY2017	cdtx	Increase In Base Rent Annual IncreaseInBaseRentAnnual	0.03
CY2016	cdtx	Maturity Period Of Short Term Investments MaturityPeriodOfShortTermInvestments	P1Y
CY2017	cdtx	Maturity Period Of Short Term Investments MaturityPeriodOfShortTermInvestments	P1Y
CY2017	cdtx	Number Of Operating Lease Options For Extension NumberOfOperatingLeaseOptionsForExtension	2	option
CY2017	cdtx	Number Of Votes Entitlement For Each Share Held NumberOfVotesEntitlementForEachShareHeld	1	vote_per_share
CY2015	cdtx	Receivable From Issuance Of Common Stock ReceivableFromIssuanceOfCommonStock	0	USD
CY2016	cdtx	Receivable From Issuance Of Common Stock ReceivableFromIssuanceOfCommonStock	0	USD
CY2017	cdtx	Receivable From Issuance Of Common Stock ReceivableFromIssuanceOfCommonStock	36000	USD
CY2017	cdtx	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit	17300000	USD
CY2015	cdtx	Vested Restricted Shares Previously Issued As Performance Based Compensation In Value VestedRestrictedSharesPreviouslyIssuedAsPerformanceBasedCompensationInValue	499000	USD
CY2016	cdtx	Vested Restricted Shares Previously Issued As Performance Based Compensation In Value VestedRestrictedSharesPreviouslyIssuedAsPerformanceBasedCompensationInValue	197000	USD
CY2017	cdtx	Vested Restricted Shares Previously Issued As Performance Based Compensation In Value VestedRestrictedSharesPreviouslyIssuedAsPerformanceBasedCompensationInValue	44000	USD
CY2015	cdtx	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	499000	USD
CY2016	cdtx	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	197000	USD
CY2017	cdtx	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	44000	USD
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001610618
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16795366	shares
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	14509000	USD
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20771151	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	102800000	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Cidara Therapeutics, Inc.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Trading Symbol TradingSymbol	CDTX
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2909000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2590000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	321000	USD
CY2015	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	42000	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	176000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	33000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3338000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4257000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1370000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2020000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	181840000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	209140000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3033000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4344000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5696000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	175000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4344000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5714000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	22000	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	5000	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18000	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2376618	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3125809	shares
CY2016Q4	us-gaap	Assets Assets	106962000	USD
CY2017Q4	us-gaap	Assets Assets	79035000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	105398000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	77670000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	19253000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22796000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62562000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	19252000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	14501000	USD
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	113000	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	21000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	30000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85367000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60813000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	39766000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22805000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-24554000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.54
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	17331	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4024470	shares
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4503686	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16837126	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20534993	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16773232	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20525688	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32201000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48158000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55735000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	466000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	265000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33451000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38583000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27309000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26364000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2030000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1722000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3646000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10232000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33500000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33451000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38583000	USD
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38600000	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	461000	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	732000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	667000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.25
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.32
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.18
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2662000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2571000	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7600000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y11M1D
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8838000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12737000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12898000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13084000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14996000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5133000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	267000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10946000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-16334000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-18947000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	341000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1650000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3389000	USD
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	18000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	77000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-235000	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1821000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	0	USD
CY2016	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2883000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1451000	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	676000	USD
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3538000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	8125000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2143000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1913000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	642000	USD
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1050000	USD
CY2016	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1760000	USD
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	453000	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	117000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	193000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	487000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	76000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1481000	USD
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	120000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	271000	USD
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7000	USD
CY2015	us-gaap	Interest Paid InterestPaid	0	USD
CY2016	us-gaap	Interest Paid InterestPaid	0	USD
CY2017	us-gaap	Interest Paid InterestPaid	511000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	733000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	704000	USD
CY2017	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P2Y
CY2016Q4	us-gaap	Liabilities Liabilities	18783000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	19291000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106962000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79035000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8909000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12085000	USD
CY2016Q4	us-gaap	Loans Payable LoansPayable	9794000	USD
CY2017Q4	us-gaap	Loans Payable LoansPayable	7206000	USD
CY2016Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2017Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2667000	USD
CY2017Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	111813000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	37094000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	20884000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-46088000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	25482000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4471000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-25959000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-39771000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-49909000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-32193000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-9789000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-11755000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-12227000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-14394000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-48165000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-13398000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-16645000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-12257000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-13428000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-55728000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	96000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	107000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	109000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30000	USD
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	31000	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015	us-gaap	Operating Expenses OperatingExpenses	32313000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	9885000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	11862000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	12336000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	14353000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	48436000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	13398000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	16615000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	12249000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	13459000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	55721000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-32313000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-48436000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-55721000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	746000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	746000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	190000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	321000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	80000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	120000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	271000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	17000	USD
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	61000	USD
CY2015	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0	USD
CY2016	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0	USD
CY2017	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	79000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1170000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	401000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	306000	USD
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	54918000	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	69617000	USD
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	19523000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	779000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2035000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	69505000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26622000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20735000	USD
CY2015	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2016	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	9947000	USD
CY2017	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	10000000	USD
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	95500000	USD
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	24300000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	387000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	525000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	228000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2744000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3064000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1374000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1044000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23475000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35699000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42823000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93662000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-149390000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-149400000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3033000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	4344000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	5714000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1860030	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.15
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	201838	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1043950	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.54
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6774000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2264000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2295393	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3099173	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.82
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.74
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2264000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3099173	shares
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.95
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.74
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.21
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.76
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2205000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M29D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M05D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M05D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4900000	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	562000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	543000	USD
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	38332	shares
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	225000	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	562000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	543000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	69271000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26622000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20771000	USD
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	18000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	525000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	228000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-11445000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	103912000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	88179000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	59744000	USD
CY2015	us-gaap	Straight Line Rent StraightLineRent	-54000	USD
CY2016	us-gaap	Straight Line Rent StraightLineRent	8000	USD
CY2017	us-gaap	Straight Line Rent StraightLineRent	29000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	108000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	356000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4600000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4642000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10756000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10800000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	248000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	921000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3965000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3365000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2149000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8600000	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9920382	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13807825	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13871938	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13910145	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16831960	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16864211	shares
CY2017Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19489375	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17500853	shares
CY2016Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16352046	shares
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font><font style="font-family:Arial;font-size:9.5pt;">—The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;font-weight:bold;">Use of Estimates</font><font style="font-family:Arial;font-size:9.5pt;">—The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s consolidated financial statements relate to estimating the fair value of the Company’s common shares used to account for share-based compensation and certain accruals, including those related to preclinical and clinical activities. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001610618-18-000011-index-headers.html	Edgar Link	pending
0001610618-18-000011-index.html	Edgar Link	pending
0001610618-18-000011.txt	Edgar Link	pending
0001610618-18-000011-xbrl.zip	Edgar Link	pending
cdtx-20171231.xml	Edgar Link	completed
cdtx-20171231.xsd	Edgar Link	pending
cdtx-20171231_cal.xml	Edgar Link	unprocessable
cdtx-20171231_def.xml	Edgar Link	unprocessable
cdtx-20171231_lab.xml	Edgar Link	unprocessable
cdtx-20171231_pre.xml	Edgar Link	unprocessable
cdtx10-k2017x12x31.htm	Edgar Link	pending
exhibit2112017-12x31.htm	Edgar Link	pending
exhibit2312017-12x31.htm	Edgar Link	pending
exhibit3112017-12x31.htm	Edgar Link	pending
exhibit3122017-12x31.htm	Edgar Link	pending
exhibit3212017-12x31.htm	Edgar Link	pending
exhibit3222017-12x31.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
performancegraph20171231a01.jpg	Edgar Link	pending
ph1pkgraph.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDTX
Cidara Therapeutics, Inc. Stock $cdtx

2018 Q1 Form 10-K Financial Statement

#000161061818000011 Filed on February 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDTX Cidara Therapeutics, Inc. Stock $cdtx

2018 Q1 Form 10-K Financial Statement

#000161061818000011 Filed on February 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDTX
Cidara Therapeutics, Inc. Stock $cdtx